News
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...
The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...
Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.
Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock dropped 6% after Sarepta Therapeutics (NASDAQ:SRPT) announced it sold over 9.2 million shares of Arrowhead in a privately negotiated ...
Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...
Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...
6h
InvestorsHub on MSNArrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...
Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...
7h
Investor's Business Daily on MSNSarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the smaller biotech ...
Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results